Recordati sees 19% rise in nine-month sales

8 November 2022

Italian drugmaker Recordati (REC: MI) today presented its annual financial results for the first nine months of 2022, edging its shares up 1.6% to 38.48 euros.

Consolidated net revenue in the first nine months of 2022 was 1,377.5 million euros ($1,378 million), up 19.1% compared to the same period of the previous year, including 91.1 million euros of 2nd-3rd quarter revenue from the rare and niche oncology product portfolio acquired with EUSA Pharma, consolidated since the second quarter.

The acquisition carried an enterprise value of around 750 million euros, and brought in EUSA products such as Qarziba (dinutuximab beta), Sylvant (siltuximab) and Fotivda (tivozanib).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK